Table 3. Meta-analyses of MTHFR C677T polymorphism and cervical cancer susceptibility after omitting the studies.
Polymorphism | OR (95% CI) | Z | P OR | I 2 (%) | P Q | Effect model |
T vs. Ca | 1.11 (0.97, 1.26) | 1.55 | 0.12 | 6 | 0.38 | F |
TT vs. CCb | 1.31 (1.01, 1.69) | 2.05 | 0.04 | 5 | 0.40 | F |
TT+CT vs. CCa | 1.12 (0.95, 1.33) | 1.34 | 0.18 | 0 | 0.56 | F |
TT vs. CT+CCc | 1.13 (0.92, 1.38) | 1.20 | 0.23 | 19 | 0.27 | F |
Abbreviations and definitions: CI, 95% confidence intervals; OR, odds ratio; P Q, P value of Q test for heterogeneity; F, fixed-effect models.
MTHFR C677T polymorphism and cervical cancer susceptibility after excluding the three studies of Shekari M et al., Ma XC et al., and Zoodsma M et al.
MTHFR C677T polymorphism and cervical cancer susceptibility after excluding the two studies of Ma XC et al. and Zoodsma M et al.
MTHFR C677T polymorphism and cervical cancer susceptibility after excluding the study of Ma XC et al.